Key result
Botulinum toxin combined with electrical stimulation and physiotherapy improves walking speed trends vs control.
RCT (n=21)
randomized
Yes
Answers are grounded in this paper and cite their sources.
The objective was to inform sample size calculations for a full randomized controlled trial (RCT). The design included an RCT pilot trial with a 16 week study period, including a 4 week baseline phase. The subjects were adults within 1 year of first stroke, ambulant with a spastic dropped foot. Twenty-one participants were recruited from the stroke services of 4 centers. For intervention all participants received physiotherapy; the treatment group also received botulinum neurotoxin Type A (BoNTA) intramuscular injections to triceps surae (800 U Dysport) and functional electrical stimulation (FES) of the common peroneal nerve to assist walking. The main outcome measure was walking speed. The result was a significant upward trend in median walking speed for both the control (p = 0.02) and treatment groups (nonstimulated p = 0.004, stimulated p = 0.042). Trend lines were different in location (p = 0.04 and p = 0.009, respectively). In conclusion, there is evidence of an additional, beneficial effect of BoNTA and FES. Sufficient information has been gained on the variability of the primary outcome measure to inform sample size calculations for a full RCT to quantify the treatment effect with precision.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2002) conducted an RCT in Spastic dropped foot in subacute stroke (n=21). Botulinum neurotoxin Type A (BoNTA) and functional electrical stimulation (FES) vs. Physiotherapy alone was evaluated on Walking speed (p=0.04 and 0.009). Botulinum neurotoxin Type A combined with functional electrical stimulation and physiotherapy resulted in significant differences in walking speed trend lines compared to control (p=0.04 and p=0.009).
Synapse has enriched 10 related papers. Consider them for comparative context: